



Supplement figure 5. Proportion of MTC control patients with Grade ≥ 3 Adverse Events (G3AEs). G3AEs were reported in 23.7% [95%CI 17.8 – 29.5; $Q=10.4$, $X^2(d.f. 1)$, $p=0.001$, $I^2=90.4\%$] of patients ($z=7.9$, $p<0.001$)